<DOC>
	<DOCNO>NCT01865266</DOCNO>
	<brief_summary>Ventilator-associated pneumonia ( VAP ) important cause morbidity mortality ventilate critically ill patient specially intensive care unit ( ICU ) . It associate increased duration mechanical ventilation , high death rate increase healthcare cost development country . Although VAP preventable many practice demonstrate reduce incidence disease , morbidity still high . VAP hard cure mortality 40 % report China 2004 . If bacteria multidrug-resistance ( MDR ) isolate , mortality increase 70 % . So much method need treat VAP addition use antibiotic . Ulinastatin serine protease inhibitor molecular weight 67,000 find healthy human urine . It use worldwide patient inflammatory disorder , include disseminate intravascular coagulation ( DIC ) , shock , pancreatitis . Furthermore , ulinastatin administration help reduce sepsis , prevent multiple organ dysfunction , modulate immune function . Actually , three study show ulinastatin treatment associate reduced level inflammatory factor blood serum patient acute respiratory distress syndrome ( ARDS ) .Though analysis serum inflammatory factor tumor necrosis factor ( TNF ) -Î± interleukin ( IL ) -6 use determine degree systemic inflammation various clinical condition , reflect degree lung infection directly . Basing result previous study , meta analysis system review , investigator hypothesize anti-inflammatory function ulinaststin may also decrease level inflammatory factor bronchoalveolar lavage ( BAL ) fluid Patients VAP . In addition prospective study investigate role ulinastatin BAL . The investigator hop study approve relationship ulinastatin inflammatory factor BAL . And improve process , outcome cost critical care well .</brief_summary>
	<brief_title>The Effect Ulinastatin Bronchoalveolar Lavage Fluid Inflammatory Factors Patients With Ventilator-associated Pneumonia</brief_title>
	<detailed_description>This one-center , three-arm , randomize , single-blinded , controlled trial . When patient diagnose VAP mechanic ventilation ICU , seal envelop open decide whether patient assign normal dose ulinastatin group , high dose ulinastatin group compare group . VAP diagnosis treatment accord `` Comprehensive evidence-based clinical practice guideline ventilator-associated pneumonia : Diagnosis treatment '' publish 2008 Canadian critical care trial group . The aim present study determine efficacy ulinastatin treatment ventilator-associated Pneumonia ( VAP ) investigate effect inflammatory factor bronchoalveolar lavage fluid .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Urinastatin</mesh_term>
	<criteria>All consecutive patient ventilatorassociated pneumonia ( VAP ) admit intensive care unit 1st January 2014 0:00 ( midnight ) finish date 31st December 2015 23:59 ( 11:59 pm ) . Informed consent . Patients pneumonia admit ICU . Ulinastatin previous use patient diagnosed VAP . Active gastropathic disorder . Be allergic ulinastatin . Pregnancy . Unwilling continue therapy hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ventilator-associated pneumonia</keyword>
	<keyword>mechanical ventilation</keyword>
	<keyword>ulinastatin injection</keyword>
	<keyword>bronchoalveolar lavage fluid</keyword>
	<keyword>inflammatory factor</keyword>
</DOC>